Open tenders for Synthon

Arzneimittel mit dem Wirkstoff Sunitinib (ATC: L01EX01)

Fits: Complex generic medicines, including active pharmaceutical ingredients and finished drug products, sold to partners and in select markets under the Synthon brand

Arzneimittel mit der Wirkstoffkombination Cinnarizin und Dimenhydrinat (ATC: N07CA22)

Fits: Complex generic medicines, including active pharmaceutical ingredients and finished drug products, sold to partners and in select markets under the Synthon brand

Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130 a Abs. 8 SGB V ab dem 01.07.2025

Fits: Complex generic medicines, including active pharmaceutical ingredients and finished drug products, sold to partners and in select markets under the Synthon brand

Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Sunitinib (ATC-Code L01EX01).

Fits: Complex generic medicines, including active pharmaceutical ingredients and finished drug products, sold to partners and in select markets under the Synthon brand

Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V (Open-House-Modell)

Fits: Complex generic medicines, including active pharmaceutical ingredients and finished drug products, sold to partners and in select markets under the Synthon brand

Medicamentos oncológicos_27FAR024

Fits: Complex generic medicines, including active pharmaceutical ingredients and finished drug products, sold to partners and in select markets under the Synthon brand

Arzneimittelverträge mit Beitrittsoption

Fits: Complex generic medicines, including active pharmaceutical ingredients and finished drug products, sold to partners and in select markets under the Synthon brand

Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130 a Abs. 8 SGB V in der Zeit von 01.01.2025 - 31.12.2026

Fits: Complex generic medicines, including active pharmaceutical ingredients and finished drug products, sold to partners and in select markets under the Synthon brand

Open House Originale Rabattverträge 2025-21 - Sofosbuvir, Velpatasvir, Voxilaprevir (Wirkstoffkombination)

Fits: Develops, manufactures and commercializes complex generic medicines for pharmaceutical partners and markets worldwide

Open House Originale Rabattverträge 2025-02- Elvitegravir/Cobicistat/Emtricitabin/Tenofoviralafenamidfumarat (Genvoya(R))

Fits: Develops, manufactures and commercializes complex generic medicines for pharmaceutical partners and markets worldwide

Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130 a Abs. 8 SGB V ab dem 01.11.2025 / 01.01.2026

Fits: Complex generic medicines, including active pharmaceutical ingredients and finished drug products, sold to partners and in select markets under the Synthon brand

Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V (Open-House-Modell)

Fits: Complex generic medicines, including active pharmaceutical ingredients and finished drug products, sold to partners and in select markets under the Synthon brand

MEDICAMENTE : SOLUTII INJECTABILE - CPV : 33692500-2 ; ANTIINFECTIOASE GENERALE PT. UZ SISTEMIC – CPV : 33651000-8 ; MEDICAMENTE PT. SISTEMUL GENITO - URINAR SI HORMONI - CPV : 33640000-8 ; SOLUTII PERFUZII - CPV: 33692400-1 ; HEPARINA - CPV: 33141550-0 ; MEDICAMENTE PENTRU SISTEMUL NERVOS SI ORGANE SENZORIALE – CPV : 33660000-4

Fits: Complex generic medicines, including active pharmaceutical ingredients and finished drug products, sold to partners and in select markets under the Synthon brand

Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Trientin (ATC-Code nach WHO: A16AX12)

Fits: Complex generic medicines, including active pharmaceutical ingredients and finished drug products, sold to partners and in select markets under the Synthon brand

Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Cinnarizin/Dimenhydrinat (ATC-Code nach WHO: N07CA52; amtlicher ATC: N07CA22)

Fits: Complex generic medicines, including active pharmaceutical ingredients and finished drug products, sold to partners and in select markets under the Synthon brand

Open House Originale Rabattverträge 2025-01 - Bictegravir/Emtricitabin/Tenofoviralafenamid (Biktarvy(R))

Fits: Develops, manufactures and commercializes complex generic medicines for pharmaceutical partners and markets worldwide

DIVERSE MEDICAMENTE

Fits: Complex generic medicines, including active pharmaceutical ingredients and finished drug products, sold to partners and in select markets under the Synthon brand

Open-House-Rabattverträge 2024-02

Fits: Complex generic medicines, including active pharmaceutical ingredients and finished drug products, sold to partners and in select markets under the Synthon brand

Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130 a Abs. 8 SGB V ab dem 01.07.2026

Fits: Complex generic medicines, including active pharmaceutical ingredients and finished drug products, sold to partners and in select markets under the Synthon brand

Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130 a Abs. 8 SGB V ab dem 01.01.2027

Fits: Complex generic medicines, including active pharmaceutical ingredients and finished drug products, sold to partners and in select markets under the Synthon brand

Multifunkční přístroj pro spektrofotometrii a fluorimetrii 2

MUNI – Cestovní pojištění 2027 - 2029

Automatizované disoluční linky s UV/VIS detekcí

Ostraha objektu RMU Žerotínovo náměstí 9, Brno a ostraha areálu RMU Komenského náměstí 2, Brno pro období 2027 - 2029

FZŠ –Technický automobil hm. kategorie „S“